We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 1,113% below its sector, cheaper than its peers on earnings.
OliX Pharmaceuticals, Inc. is a biotechnology firm in the clinical development phase, specializing in the creation of RNA interference (RNAi) treatments. Its primary focus lies in developing therapies for various conditions affecting the skin (dermal), eyes (ophthalmic), and lungs (pulmonary). The company maintains a robust pipeline of experimental medicines, including: For dermatological applications: OLX101 (targeting skin scars), OLX102 (for skin whitening), OLX103 (an atopic dermatitis candidate), OLX104 (addressing hair loss), OLX105 (an anti-wrinkle product), and OLX106 (for diabetic foot ulcers). For ophthalmic disorders: OLX301 (for age-related macular degeneration retinal fibrosis) and OLX304 (for retinitis pigmentosa). For respiratory diseases: OLX201 (lung fibrosis), OLX202 (asthma), and OLX203 (influenza). Other significant programs encompass: OLX401 (neuropathic pain), OLX701 (liver fibrosis), and a distinct OLX701 designated for cancer immunotherapy. Furthermore, OliX Pharmaceuticals has forged strategic partnerships, including a collaborative agreement with Théa to advance SiRNA therapeutics for eye-related diseases, and a research alliance with PCI Biotech Holding ASA. Established in 2010, the company's operations are based in Suwon, South Korea.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 226950.KQ and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
